European Cruise
08/09/2026 - 08/20/2026
8:00 am - 1:00 pm
Where: departing from London
Topics include: topics: diabetes
European Cruise
CRUISE INFO:
aboard Norwegian Cruise Line’s Norwegian Sky
Group rate is Sold Out. Cabins are still available at ncl.com. YOU MUST REGISTER FOR THE CLASSES HERE TO HAVE A SEAT IN THE SEMINARS.
If you make your reservation on your own, please let us know. You will still need to register for the lectures at the bottom of this page. Seating is limited.
August 9, 2026—depart from London
August 10th—lecture day 8am to 1pm
August 11th—Edinburgh, Scotland
August 12th—Inverness, Scotland
August 13th—Portree, England
August 14th—Belfast, Ireland
August 15th—Dublin, Ireland
August 16th—lecture day 8am to 1pm
August 17th—Amsterdam, Netherlands
August 18th—Brussels, Belgium
August 19th—Paris, France
August 20th–return to London
Dr. Joshua Neumiller, Pharm D., CDCES, FADCES, FASCP
Washington State University
Joshua Neumiller is Vice-Chair and Professor in the Department of Pharmacotherapy at Washington State University (WSU). Josh is a contributing author of the ADA books Medication for the Treatment of Diabetes and Practical Insulin. He is past Editor-in-Chief for the ADA journal Diabetes Spectrum and served as Chairman of the ADA’s Professional Practice Committee from 2018-2019 whose primary responsibility is revising the ADA Standards of Medical Care in Diabetes each year. In addition to his work at WSU, Josh holds a research appointment with Providence Medical Research Center (PMRC) in Spokane, Washington and is an investigator with the Center for Kidney Disease Research, Education and Hope (CURE-CKD). Josh was the 2021 ADCES Diabetes CARE & Education Specialist of the Year and is the President of Health Care & Education for the American Diabetes Association.
Monday August 10, 2026
DIABETES & DIABETES COMPLICATIONS: AN UPDATE ON STANDARDS OF CARE AND OPTIMIZATION OF THERAPIES
ACPE# TBA
Objectives:
1. Review epidemiologic data for diabetes and diabetes-related complications.
2. Discuss current standard of care recommendations for intensification of glucose-lowering therapies to meet individualized glycemic goals.
3. Appreciate the importance of considering key comorbidities (e.g., cardiovascular disease, kidney disease, heart failure, liver disease) when formulating a person-specific diabetes treatment plan.
4. Recall current targets and recommendations for blood pressure and cholesterol management in diabetes to mitigate risk of complications.
5. Develop a person-centered treatment plan when presented with a diabetes patient case.
——————————————————————————————————————————————————————————————–
Sunday August 16, 2026
SAFETY FIRST: A CASE-BASED DISCUSSION ON KEY SIDE EFFECTS, TOLERABILITY, AND COUNSELING CONSIDERATIONS IN METABOLIC MANAGEMENT
ACPE# TBA
Objectives:
1. List common, rare, and controversial adverse event and safety considerations with glucose-lowering therapies.
2. Discuss key safety considerations for use of glucose-lowering therapies in patients with key comorbidities (e.g. chronic kidney disease) and/or advancing age.
3. Review key risk mitigation strategies when initiating glucose-lowering medications.
4. Discuss the role of continuous glucose monitoring (CGM) in informing medication adjustments and optimizing safe use of glucose-lowering agents.
5. Develop a person-centered risk mitigation and counseling plan when presented with a diabetes patient case.